Drug intelligence / Profile preview

MSC-Apceth

Development stage: Unknown
Lead developer: Apceth
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

MSC-Apceth is an autologous cell therapy consisting of GMP-manufactured, ex-vivo expanded CD34-negative, non-hematopoietic bone marrow-derived mesenchymal stem cells (MSCs). Developed by Apceth GmbH & Co. KG, it is designed to treat critical limb ischemia (CLI) and advanced peripheral arterial occlusive disease (PAOD). The therapy leverages the proangiogenic and tissue-regenerative properties of MSCs to promote the formation of new blood vessels in ischemic tissues. It has been evaluated in a Phase I/II clinical trial (NCT01351610) where it was administered intravenously following percutaneous transluminal angioplasty (PTA).

Other names: autologous CD34-negative bone marrow-derived mesenchymal stem cells

Beyond the preview

Go deeper on MSC-Apceth.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSC-Apceth.

Explore the full profile